733 related articles for article (PubMed ID: 24986688)
1. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
[TBL] [Abstract][Full Text] [Related]
2. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
[TBL] [Abstract][Full Text] [Related]
3. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
Frigault MJ; Lee J; Basil MC; Carpenito C; Motohashi S; Scholler J; Kawalekar OU; Guedan S; McGettigan SE; Posey AD; Ang S; Cooper LJ; Platt JM; Johnson FB; Paulos CM; Zhao Y; Kalos M; Milone MC; June CH
Cancer Immunol Res; 2015 Apr; 3(4):356-67. PubMed ID: 25600436
[TBL] [Abstract][Full Text] [Related]
4. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.
Guedan S; Madar A; Casado-Medrano V; Shaw C; Wing A; Liu F; Young RM; June CH; Posey AD
J Clin Invest; 2020 Jun; 130(6):3087-3097. PubMed ID: 32069268
[TBL] [Abstract][Full Text] [Related]
5. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
Wyatt MM; Huff LW; Nelson MH; Neal LR; Medvec AR; Rangel Rivera GO; Smith AS; Rivera Reyes AM; Knochelmann HM; Riley JL; Lesinski GB; Paulos CM
Mol Ther; 2023 Jul; 31(7):2120-2131. PubMed ID: 37081789
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
[TBL] [Abstract][Full Text] [Related]
7. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
[TBL] [Abstract][Full Text] [Related]
8. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369
[TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.
Salter AI; Ivey RG; Kennedy JJ; Voillet V; Rajan A; Alderman EJ; Voytovich UJ; Lin C; Sommermeyer D; Liu L; Whiteaker JR; Gottardo R; Paulovich AG; Riddell SR
Sci Signal; 2018 Aug; 11(544):. PubMed ID: 30131370
[TBL] [Abstract][Full Text] [Related]
10. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
11. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.
Paulos CM; Carpenito C; Plesa G; Suhoski MM; Varela-Rohena A; Golovina TN; Carroll RG; Riley JL; June CH
Sci Transl Med; 2010 Oct; 2(55):55ra78. PubMed ID: 20980695
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.
Cheng Z; Wei R; Ma Q; Shi L; He F; Shi Z; Jin T; Xie R; Wei B; Chen J; Fang H; Han X; Rohrs JA; Bryson P; Liu Y; Li QJ; Zhu B; Wang P
Mol Ther; 2018 Apr; 26(4):976-985. PubMed ID: 29503204
[TBL] [Abstract][Full Text] [Related]
13. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
[TBL] [Abstract][Full Text] [Related]
15. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2
Dai Q; Han P; Qi X; Li F; Li M; Fan L; Zhang H; Zhang X; Yang X
Front Immunol; 2020; 11():539654. PubMed ID: 33281809
[TBL] [Abstract][Full Text] [Related]
17. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
18. Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.
Oelsner S; Friede ME; Zhang C; Wagner J; Badura S; Bader P; Ullrich E; Ottmann OG; Klingemann H; Tonn T; Wels WS
Cytotherapy; 2017 Feb; 19(2):235-249. PubMed ID: 27887866
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Lee SY; Olsen P; Lee DH; Kenoyer AL; Budde LE; O'Steen S; Green DJ; Heimfeld S; Jensen MC; Riddell SR; Press OW; Till BG
J Immunother; 2018 Jan; 41(1):19-31. PubMed ID: 29176334
[TBL] [Abstract][Full Text] [Related]
20. CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation.
Kofler DM; Chmielewski M; Rappl G; Hombach A; Riet T; Schmidt A; Hombach AA; Wendtner CM; Abken H
Mol Ther; 2011 Apr; 19(4):760-7. PubMed ID: 21326215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
